KR102839924B1 - 티오펜 유도체의 결정형 - Google Patents

티오펜 유도체의 결정형

Info

Publication number
KR102839924B1
KR102839924B1 KR1020207034757A KR20207034757A KR102839924B1 KR 102839924 B1 KR102839924 B1 KR 102839924B1 KR 1020207034757 A KR1020207034757 A KR 1020207034757A KR 20207034757 A KR20207034757 A KR 20207034757A KR 102839924 B1 KR102839924 B1 KR 102839924B1
Authority
KR
South Korea
Prior art keywords
ethoxy
methylsulfonyl
methoxyphenyl
ethyl
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207034757A
Other languages
English (en)
Korean (ko)
Other versions
KR20210022556A (ko
Inventor
동레이 장
리유 왕
유군 창
Original Assignee
톈진 헤메이 파마슈티칼 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 톈진 헤메이 파마슈티칼 컴퍼니 리미티드 filed Critical 톈진 헤메이 파마슈티칼 컴퍼니 리미티드
Publication of KR20210022556A publication Critical patent/KR20210022556A/ko
Application granted granted Critical
Publication of KR102839924B1 publication Critical patent/KR102839924B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
KR1020207034757A 2018-05-02 2019-04-30 티오펜 유도체의 결정형 Active KR102839924B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810407741.X 2018-05-02
CN201810407741 2018-05-02
PCT/CN2019/085327 WO2019210864A1 (zh) 2018-05-02 2019-04-30 噻吩衍生物的晶型

Publications (2)

Publication Number Publication Date
KR20210022556A KR20210022556A (ko) 2021-03-03
KR102839924B1 true KR102839924B1 (ko) 2025-07-29

Family

ID=68386284

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020207034757A Active KR102839924B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형
KR1020207034790A Ceased KR20210022557A (ko) 2018-05-02 2019-04-30 티오펜 유도체의 고체 형태
KR1020207033658A Active KR102686835B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형
KR1020207033791A Active KR102701245B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207034790A Ceased KR20210022557A (ko) 2018-05-02 2019-04-30 티오펜 유도체의 고체 형태
KR1020207033658A Active KR102686835B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형
KR1020207033791A Active KR102701245B1 (ko) 2018-05-02 2019-04-30 티오펜 유도체의 결정형

Country Status (14)

Country Link
US (4) US11396518B2 (https=)
EP (5) EP3789389B1 (https=)
JP (5) JP2021523935A (https=)
KR (4) KR102839924B1 (https=)
CN (7) CN116813637A (https=)
AU (4) AU2019263865B2 (https=)
BR (4) BR112020021976A2 (https=)
CA (4) CA3213055A1 (https=)
DK (1) DK3789389T3 (https=)
ES (1) ES3047059T3 (https=)
FI (1) FI3789389T3 (https=)
PL (1) PL3789389T3 (https=)
PT (1) PT3789389T (https=)
WO (4) WO2019210864A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116813637A (zh) 2018-05-02 2023-09-29 天津合美医药科技有限公司 噻吩衍生物的晶型
WO2025103428A1 (zh) * 2023-11-14 2025-05-22 赣州和美药业股份有限公司 中重度斑块型银屑病的治疗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018231604A1 (en) * 2017-06-13 2018-12-20 Biotheryx, Inc. Bicyclic compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
AU2003243153A1 (en) * 2002-04-23 2003-11-10 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
BRPI1012770B8 (pt) 2009-05-14 2021-05-25 Tianjin Hemay Bio Tech Co Ltd derivados de tiofeno
WO2012000499A1 (en) 2010-06-30 2012-01-05 Leo Pharma A/S New polymorphic form of a calcimimetic compound
WO2015082583A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
IL297649A (en) 2014-07-18 2022-12-01 Green Cross Corp Crystalline form of 5-chloro-m ({5)-2-oxo-3-[4-(6,5-dihydro-4-[1,2,4]triazin-1yl)phenyl}-1,3- Oxazolidine-5-yl} methyl) thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
CN107417626B (zh) * 2016-05-23 2020-01-24 江苏奥赛康药业有限公司 一种2-氨基嘧啶类化合物的多晶型形式
CN107474057B (zh) * 2016-06-07 2021-03-12 天津药物研究院有限公司 (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
ES2979170T3 (es) * 2017-06-30 2024-09-24 Trophy Aparato de formación de imágenes dentales extraorales con detección de accesorios para el posicionamiento del paciente
CN116813637A (zh) * 2018-05-02 2023-09-29 天津合美医药科技有限公司 噻吩衍生物的晶型

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018231604A1 (en) * 2017-06-13 2018-12-20 Biotheryx, Inc. Bicyclic compounds and methods of use

Also Published As

Publication number Publication date
EP3789389A4 (en) 2022-01-26
EP4335515A2 (en) 2024-03-13
KR20210022557A (ko) 2021-03-03
BR112020022190A2 (pt) 2021-02-02
EP3789389A1 (en) 2021-03-10
CN110437250B (zh) 2023-06-23
WO2019210864A1 (zh) 2019-11-07
CN110437250A (zh) 2019-11-12
EP3789387A4 (en) 2021-06-30
AU2019262284A1 (en) 2020-12-24
AU2019262282B2 (en) 2022-04-28
WO2019210865A1 (zh) 2019-11-07
KR102701245B1 (ko) 2024-08-30
EP3789388B1 (en) 2024-01-24
JP7477459B2 (ja) 2024-05-01
US20210139498A1 (en) 2021-05-13
DK3789389T3 (da) 2025-11-10
CN116813637A (zh) 2023-09-29
BR112020022186A2 (pt) 2021-02-02
EP3789387B1 (en) 2024-02-28
EP3789387A1 (en) 2021-03-10
AU2019262286B2 (en) 2022-08-11
EP3789388A4 (en) 2021-06-09
US20210380600A1 (en) 2021-12-09
US20210230181A1 (en) 2021-07-29
AU2019263865A1 (en) 2020-12-24
CN110437251A (zh) 2019-11-12
CA3099071A1 (en) 2019-11-07
KR20210025001A (ko) 2021-03-08
CN110437249A (zh) 2019-11-12
CN110437251B (zh) 2023-07-21
AU2019262282A1 (en) 2020-11-12
US12227514B2 (en) 2025-02-18
US20210238191A1 (en) 2021-08-05
CA3213055A1 (en) 2019-11-07
BR112020021976A2 (pt) 2021-01-26
CA3098927C (en) 2023-10-03
US11396518B2 (en) 2022-07-26
AU2019262286A1 (en) 2020-11-12
KR102686835B1 (ko) 2024-07-22
CN116854705A (zh) 2023-10-10
JP2021523890A (ja) 2021-09-09
JP2021523935A (ja) 2021-09-09
EP4335515A3 (en) 2024-07-03
CN116947878A (zh) 2023-10-27
PL3789389T3 (pl) 2026-03-16
EP3800190A4 (en) 2022-01-26
US11274104B2 (en) 2022-03-15
BR112020021945A2 (pt) 2021-01-26
CA3098931C (en) 2023-10-24
CN110437249B (zh) 2023-07-21
AU2019263865B2 (en) 2022-01-27
WO2019210869A1 (zh) 2019-11-07
FI3789389T3 (fi) 2025-11-19
EP3800190A1 (en) 2021-04-07
JP2021523891A (ja) 2021-09-09
CA3098931A1 (en) 2019-11-07
EP3789388A1 (en) 2021-03-10
ES3047059T3 (en) 2025-12-03
US12180222B2 (en) 2024-12-31
CA3098927A1 (en) 2019-11-07
KR20210025000A (ko) 2021-03-08
WO2019210867A1 (zh) 2019-11-07
JP7481263B2 (ja) 2024-05-10
CA3099072A1 (en) 2019-11-07
JP2024026251A (ja) 2024-02-28
JP7542523B2 (ja) 2024-08-30
CN116836178A (zh) 2023-10-03
JP2021522348A (ja) 2021-08-30
KR20210022556A (ko) 2021-03-03
PT3789389T (pt) 2025-12-17
EP3789389B1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
KR102839924B1 (ko) 티오펜 유도체의 결정형
CA3099071C (en) Crystal forms of thiophene derivatives
HK40048511A (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40048512B (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40047648B (en) Crystalline form of (s)‑n‑[5‑[1‑(3‑ethoxy‑4‑methoxyphenyl)‑2‑(methylsulfonyl)ethyl]‑4,6‑dioxo‑5,6‑dihydro‑4h‑thieno[3,4‑c]pyrrole‑1‑yl]acetamide
HK40048512A (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40047648A (en) Crystalline form of (s)‑n‑[5‑[1‑(3‑ethoxy‑4‑methoxyphenyl)‑2‑(methylsulfonyl)ethyl]‑4,6‑dioxo‑5,6‑dihydro‑4h‑thieno[3,4‑c]pyrrole‑1‑yl]acetamide
HK40048511B (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40047649A (en) Solid form of thiophene derivative

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)